@article {44011,
	title = {Repurposing Ivacaftor for treatment of staphylococcus aureus infections},
	journal = {International Journal of Antimicrobial Agents},
	volume = {50},
	year = {2017},
	month = {SEP},
	pages = {389-392},
	type = {Journal Article},
	abstract = {<p>Drug repurposing of non-antimicrobials is a novel method to augment a seriously depleted drug pipeline for targeting drug{\textendash}resistant pathogens. This article highlights the potent antimicrobial activity of Ivacaftor against Staphylococcus aureus, including vancomycin{\textendash} and other multidrug{\textendash}resistant strains. The potent activity of Ivacaftor in vivo is also demonstrated in a murine neutropenic thigh infection model. Taken together, these results support the potential of Ivacaftor as an antimicrobial agent for the treatment of staphylococcal infections. {\textcopyright} 2017 Elsevier B.V. and International Society of Chemotherapy</p>},
	doi = {10.1016/j.ijantimicag.2017.03.020},
	author = {Thakare, R. and Das, S. and Vasudevan, N. and Jachak, G.R. and Reddy, D.S. and Dasgupta, A. and Chopra, S.},
	editor = {Singh, A. K.}
}
@article {45550,
	title = {Scalable synthesis of both enantiomers of vigabatrin, an antiepileptic drug},
	journal = {European Journal of Organic Chemistry},
	year = {2019},
	month = {FEB},
	pages = {1257{\textendash}1260},
	type = {Article},
	abstract = {<p>Vigabatrin is a potent inhibitor of gamma-aminobutyric acid (GABA) catabolism used for the treatment of epilepsy. Here we have synthesized both enantiomers of the drug vigabatrin in five steps from known intermediates using Wittig olefination and pyrolytic elimination as key steps. The target compounds are synthesized in gram scale amounts with \&gt;98 \% enantiopurity.</p>
},
	doi = {10.1002/ejoc.201801617},
	author = {Jachak, G.R. and Reddy, D.S.}
}
